Adoption of Biosimilars: Prescriber, Pharmacy and Payer Perspectives
This activity is supported by educational funding provided by Amgen and Merck Sharp & Dohme Corp.
On-demand 4-part Medical Crossfire
Adoption of Biosimilars: Prescriber, Pharmacy and Payer Perspectives
Activity Overview
This 4-part online CE-accredited activity will serve as an update on the clinical options in Biosimilars and the changing environment for clinicians, specialty pharmacists, and payers. To view each activity, click on the hyperlinks below.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025
- Eating Behaviors May Predict GLP-1 Therapy Success in Type 2 Diabetes
September 18th 2025